or Try an Advanced Search...

    Technical Analysis for PCSA - Processa Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 2.02 -7.34% -0.16
    PCSA closed down 7.34 percent on Wednesday, May 15, 2024, on 6 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical PCSA trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Fell Below 50 DMA Bearish 0.00%
    Wide Bands Range Expansion 0.00%
    50 DMA Support Bullish -7.34%
    Earnings Movers Other -7.34%
    Wide Bands Range Expansion -7.34%
    Crossed Above 50 DMA Bullish -9.01%
    Earnings Movers Other -9.01%
    Wide Bands Range Expansion -9.01%
    Gapped Up Strength -9.01%
    Older End-of-Day Signals for PCSA ...

       Recent Intraday Alerts

    Alert Time
    Down 10% about 10 hours ago
    Down 5% about 11 hours ago
    Fell Below 20 DMA about 11 hours ago
    Down 3% about 12 hours ago
    60 Minute Opening Range Breakdown about 13 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    PCSA Chart by TradingView
    Basic chart:

    Profile

    Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its product pipeline is PCS499, which is use for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on October 2, 2017 and is headquartered in Hanover, MD.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Drug Products

    Is PCSA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 6 Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
    Apr 30 Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
    Apr 26 Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Apr 25 Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Apr 25 POET, PCSA and BRFH are among premarket gainers
    Apr 11 Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
    Apr 7 Insider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40k
    Mar 28 Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
    Mar 25 Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
    Feb 21 Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
    See more PCSA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 18.0
    52 Week Low 1.4
    Average Volume 1,807,350
    200-Day Moving Average 5.58
    50-Day Moving Average 2.16
    20-Day Moving Average 2.07
    10-Day Moving Average 2.24
    Average True Range 0.26
    RSI (14) 46.52
    ADX 22.06
    +DI 27.33
    -DI 23.61
    Chandelier Exit (Long, 3 ATRs) 1.91
    Chandelier Exit (Short, 3 ATRs) 2.17
    Upper Bollinger Bands 2.68
    Lower Bollinger Band 1.45
    Percent B (%b) 0.46
    BandWidth 59.45
    MACD Line 0.01
    MACD Signal Line 0.01
    MACD Histogram 0.0058
    Fundamentals Value
    Market Cap 3.45 Million
    Num Shares 1.71 Million
    EPS -22.80
    Price-to-Earnings (P/E) Ratio -0.09
    Price-to-Sales 0.00
    Price-to-Book 0.55
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.43
    Resistance 3 (R3) 2.45 2.34 2.36
    Resistance 2 (R2) 2.34 2.24 2.33 2.33
    Resistance 1 (R1) 2.18 2.17 2.13 2.16 2.31
    Pivot Point 2.07 2.07 2.04 2.06 2.07
    Support 1 (S1) 1.91 1.97 1.86 1.89 1.73
    Support 2 (S2) 1.80 1.90 1.79 1.71
    Support 3 (S3) 1.64 1.80 1.68
    Support 4 (S4) 1.62